Data as of Apr 15
| +0.08 / +0.97%|
The 10 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 15.50, with a high estimate of 23.00 and a low estimate of 9.00. The median estimate represents a +86.07% increase from the last price of 8.33.
The current consensus among 12 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.